A Phase II Randomized Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (GU17-289)

R
Roberto Pili, MD

Primary Investigator

Overview

The purpose of this study is to compare any good and bad effects of using a high dose Interleukin (IL-2) and Entinostat to using IL-2 alone. The addition of Entinostat to high dose IL-2 could shrink your cancer/prevent it from returning for a longer period of time but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.

Description

The purpose of this study is to estimate and compare progression free survival (PFS) in patients receiving high dose interleukin 2 or high dose interleukin 2 plus entinostat.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    renal cell carcinoma,kidney cancer,metastatic clear cell renal cell carcinoma
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Patients must have pathological diagnosis of renal cell carcinoma that is metastatic or surgically unresectable. The histology must be clear cell carcinoma or predominant clear cell carcinoma.
  • Up to two prior therapies for RCC are allowed. One prior therapy must contain an immune checkpoint inhibitor. Prior palliative radiation to metastatic lesion(s) is permitted, provided there is at least one measurable and/or evaluable lesion(s) that has not been irradiated.

For a full list of participation criteria, please visit clinicaltrials.gov.


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1712301349

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center